trial · primary record
Pidnarulex
Metastatic Castration Resistant Prostate Cancer (mCRPC)
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 4 |
| Primary completion | 2025-10-01 |
| Primary endpoint | The MTD is defined as the highest tolerable dose of pidnarulex when talazoparib is given at the highest tolerable dose and the highest dose of pidnarulex when talazoparib is given at the lowest dose (two MTDs will be estimated). |
| Registry ID | NCT05425862 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:22.980Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05425862
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.